Bacil Pharma Ltd

Bacil Pharma Ltd

Bacil Pharma Ltd has announced its unaudited financial results for the quarter and half year ended September 30, 2026, with revenue from operations at Rs. 918 lakhs and profit from ordinary activities after tax at Rs. 625 lakhs.

Bacil Pharma Ltd

Bacil Pharma Ltd has announced its unaudited financial results for the half year and quarter ended September 30, 2026, with a profit of Rs. 1529 lakhs and EPS of Rs. 0.03.

Bacil Pharma Ltd

Bacil Pharma Ltd has submitted a compliance certificate under Regulation 74 (5) of SEBI (DP) Regulations, 2018 for the period ended 30th September, 2026, confirming the dematerialization of securities and listing on stock exchanges.

Bacil Pharma Ltd

Bacil Pharma Ltd has announced the resignation of its Whole-Time Company Secretary, Mr. Dikshant Singh Panwar, effective October 8, 2026, due to increasing personal and professional commitments.

Bacil Pharma Ltd

Bacil Pharma Ltd has scheduled a Board Meeting on 14th October, 2026 to consider and approve unaudited financial results for the half-yearly and quarter ended 30th September, 2026.

Bacil Pharma Ltd

Bacil Pharma Ltd has announced the closure of its trading window for the quarter and half year ended 30th September 2026, effective from 1st October 2026, until 48 hours after the conclusion of the Board of Directors meeting to consider the unaudited financial results.

Bacil Pharma Ltd

Bacil Pharma Ltd has submitted the Scrutinizer Report for its 39th Annual General Meeting (AGM) held on September 23, 2026, through remote e-voting and two-way video conferencing.

Bacil Pharma Ltd

Bacil Pharma Ltd held its 39th Annual General Meeting (AGM) on September 23, 2026, through two-way video conferencing. The meeting was attended by 66 members. The company adopted its audited financial statements for the year ended March 31, 2026, and passed several resolutions, including the re-appointment of directors and the appointment of statutory auditors.

Bacil Pharma Ltd

Bacil Pharma Ltd has submitted its annual report for the financial year 2025-2026, along with a notice calling its 39th annual general meeting. The report includes the audited financial statements, directors' report, corporate governance report, and other related documents.

Bacil Pharma Ltd

Bacil Pharma Ltd has announced the notice of its 39th Annual General Meeting (AGM) to be held on September 23, 2026, through video conferencing or other audio-visual means. The meeting will consider the audited financial statements for the year ended March 31, 2026, and the re-appointment of Ms. Chaitali Kalpataru Shah as a director.

Bacil Pharma Ltd

Bacil Pharma Ltd has announced a book closure for the purpose of its 39th Annual General Meeting, scheduled on September 23, 2026. The book closure period will be from September 17 to 23, 2026. No dividend has been declared for the financial year 2025-2026.

Bacil Pharma Ltd

Bacil Pharma Ltd has announced the outcome of its board meeting held on August 29, 2026, where the board approved the notice of the 39th Annual General Meeting to be held on September 23, 2026, and approved the Director's Report for the financial year ended March 31, 2026.

Bacil Pharma Ltd

Bacil Pharma Ltd has scheduled a Board Meeting on 29th August, 2026 to discuss and approve various matters including the 39th Annual General Meeting, Director Report for FY 2025-2026, and fixing the date, place, and timing of the AGM.

Bacil Pharma Ltd

Bacil Pharma Ltd has appointed two new directors, Mr. Mahesh Singh and Mr. Anil Shiv Charan Singh, as non-executive independent and non-executive directors, respectively, subject to member approval.

Bacil Pharma Ltd

Bacil Pharma Ltd's Board of Directors approved the appointment of two new directors, Mr. Mahesh Singh and Mr. Anil Shiv Charan Singh, as non-executive independent directors, subject to member approval.

Bacil Pharma Ltd

Bacil Pharma Ltd has informed BSE that a Board meeting is scheduled on 25th August 2026 to discuss the appointment of directors and any other business with the permission of the chairperson.

Bacil Pharma Ltd

Bacil Pharma Ltd has announced unaudited financial results for the quarter ended 30th June, 2026. The company reported a profit of ₹30.12 lakhs, with earnings per share (EPS) of ₹0.22. The results have been reviewed and approved by the Audit Committee and the Board of Directors. The statutory auditors have carried out a 'Limited Review' of the results as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Bacil Pharma Ltd

Bacil Pharma Ltd has announced its unaudited financial results for the quarter ended 30th June, 2026, with a profit of ₹30.12 crores and an EPS of ₹0.22.

Bacil Pharma Ltd

Bacil Pharma Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 12/08/2026 to consider and approve unaudited financial results for the quarter ended 30/06/2026.

Bacil Pharma Ltd

Bacil Pharma Ltd has incorporated a wholly owned subsidiary named Bacil Research & Development Private Limited. The company has informed the BSE under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.